OM
TVRD

Opaleye Management’s Tvardi Therapeutics TVRD Stock Holding History

Opaleye Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,222
Closed -$8.04M – 51
2019
Q3 		$8.04M Buy
+12,222
New +$10.2M 2.91% 12
2019
Q2 		– Sell
-5,556
Closed -$3.92M – 53
2019
Q1 		$3.92M Buy
+5,556
New +$3.33M 1.09% 35
2018
Q4 		– Sell
-3,611
Closed -$3.11M – 55
2018
Q3 		$3.11M Buy
+3,611
New +$2.61M 0.79% 33
2017
Q2 		– Sell
-10,694
Closed -$7.08M – 50
2017
Q1 		$7.08M Sell
10,694
-2,500
-19% -$1.34M 3.52% 7
2016
Q4 		$4.41M Sell
13,194
-5,556
-30% -$1.78M 2.6% 14
2016
Q3 		$5.64M Sell
18,750
-4,444
-19% -$963K 2.95% 8
2016
Q2 		$4.02M Sell
23,194
-556
-2% -$121K 2.68% 12
2016
Q1 		$5.32M Buy
23,750
+11,889
+100% +$3.55M 3.32% 8
2015
Q4 		$7.2M Buy
11,861
+333
+3% +$183K 3.01% 13
2015
Q3 		$5.93M Buy
11,528
+2,084
+22% +$1.4M 2.92% 14
2015
Q2 		$4.13M Buy
9,444
+694
+8% +$268K 1.64% 24
2015
Q1 		$3.17M Buy
8,750
+6,528
+294% +$2.47M 1.47% 26
2014
Q4 		$798K Buy
+2,222
New +$716K 0.4% 35

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Opaleye Management's TVRD Position: Q4 2019 in Review

Opaleye Management sold out of Tvardi Therapeutics (TVRD) in Q4 2019, closing a stake of 12,222 shares — an estimated $8.04M sold.

Opaleye Management first reported a position in TVRD in Q4 2014 and held it in 13 quarters. The position peaked at $8.04M in Q3 2019. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • Opaleye Management reported no remaining Tvardi Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Opaleye Management sold 12,222 Tvardi Therapeutics shares in Q4 2019, an estimated $8.04M.
  • Opaleye Management first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 13 quarters.
  • Opaleye Management's Tvardi Therapeutics position peaked at $8.04M in Q3 2019.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on Opaleye Management's 13F filing for Q4 2019, filed 14 Feb 2020.